↓ Skip to main content

Progressive hemifacial atrophy: a review

Overview of attention for article published in Orphanet Journal of Rare Diseases, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
106 Dimensions

Readers on

mendeley
125 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Progressive hemifacial atrophy: a review
Published in
Orphanet Journal of Rare Diseases, April 2015
DOI 10.1186/s13023-015-0250-9
Pubmed ID
Authors

Stanislav N Tolkachjov, Nirav G Patel, Megha M Tollefson

Abstract

Progressive Hemifacial Atrophy (PHA) is an acquired, typically unilateral, facial distortion with unknown etiology. The true incidence of this disorder has not been reported, but it is often regarded as a subtype of localized scleroderma. Historically, a debate existed whether PHA is a form of linear scleroderma, called morphea en coup de sabre (ECDS), or whether these conditions are inherently different processes or appear on a spectrum (; Adv Exp Med Biol 455:101-4, 1999; J Eur Acad Dermatol Venereol 19:403-4, 2005). Currently, it is generally accepted that both diseases exist on a spectrum of localized scleroderma and often coexist. The pathogenesis of PHA has not been delineated, but trauma, autoimmunity, infection, and autonomic dysregulation have all been suggested. The majority of patients have initial manifestations in the first two decades of life; however, late presentations in 6th and 7th decades are also described [J Am Acad Dermatol 56:257-63, 2007; J Postgrad Med 51:135-6, 2005; Neurology 61:674-6, 2003]. The typical course of PHA is slow progression over 2-20 years and eventually reaching quiescence. Systemic associations of PHA are protean, but neurological manifestations of seizures and headaches are common [J Am Acad Dermatol 56:257-63, 2007; Neurology 48:1013-8, 1997; Semin Arthritis Rheum 43:335-47, 2013]. As in many rare diseases, standard guidelines for imaging, treatment, and follow-up are not defined. This review is based on a literature search using PubMed including original articles, reviews, cases and clinical guidelines. The search terms were "idiopathic hemifacial atrophy", "Parry-Romberg syndrome", "Romberg's syndrome", "progressive hemifacial atrophy", "progressive facial hemiatrophy", "juvenile localized scleroderma", "linear scleroderma", and "morphea en coup de sabre". The goal of this review is to summarize clinical findings, theories of pathogenesis, diagnosis, clinical course, and proposed treatments of progressive hemifacial atrophy using a detailed review of literature. Review articles were used to identify primary papers of interest while retrospective cohort studies, case series, case reports, and treatment analyses in the English language literature or available translations of international literature were included.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Unknown 124 99%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 15 12%
Student > Bachelor 14 11%
Student > Master 13 10%
Student > Ph. D. Student 12 10%
Researcher 12 10%
Other 25 20%
Unknown 34 27%
Readers by discipline Count As %
Medicine and Dentistry 72 58%
Nursing and Health Professions 4 3%
Business, Management and Accounting 2 2%
Psychology 2 2%
Biochemistry, Genetics and Molecular Biology 1 <1%
Other 4 3%
Unknown 40 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2022.
All research outputs
#2,862,929
of 23,376,718 outputs
Outputs from Orphanet Journal of Rare Diseases
#388
of 2,684 outputs
Outputs of similar age
#37,890
of 265,878 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#7
of 40 outputs
Altmetric has tracked 23,376,718 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,684 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,878 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.